Health Care Sector Update for 12/06/2018: KNSA, EARS, SUPN

Shutterstock photo

Top Health Care Stocks

JNJ, -0.9%

PFE, -1.4%

MRK, -0.4%

ABT, -1.2%

AMGN, -0.6%

Health care stocks extended their declines through Thursday’s afternoon trading, with the NYSE Health Care Index dropping to a 1.6% retreat this afternoon while shares of health care companies in the S&P 500 were down 1.4% as a group.

In company news, Kiniksa Pharmaceuticals ( KNSA ) shares fell more than 14% after the company said the U.S. Food and Drug Administration placed its recently submitted new drug application for mavrilimumab on clinical hold. The FDA requested for additional information regarding the delivery device to be used in Kiniksa’s phase 2 clinical trial of mavrilimumab in giant cell arteritis. The company clarified that the device-related information request is not connected to preclinical toxicology data nor the design of the phase 2 trial.

In other sector news,

(+) Auris Medical ( EARS ) Receives an orphan drug designation and agreed to acquire certain patents on betahistine.

(-) Supernus Pharmaceuticals ( SUPN ) Two phase 3 studies of SPN-812, aimed to treat attention deficit hyperactivity disorder, or ADHD, in children, achieves primary endpoints

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Copyright (C) 2016 All rights reserved. Unauthorized reproduction is strictly prohibited.

Zeen is a next generation WordPress theme. It’s powerful, beautifully designed and comes with everything you need to engage your visitors and increase conversions.

Wealth Empire Newsletter
Register now for free updates and alerts

Subscribe By

Note: I have the ability to revoke this permission at any time and ask for the removal of my personal data collected by contacting us or simply clicking Unsubscribe.